Clinical Trial Update: Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study

View source ↗

Summary

A multicenter prospective study aims to predict response to selinexor-based therapy in relapsed/refractory multiple myeloma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• XPOVIO (selinexor)

Snippet

Sponsor: Shanxi Bethune Hospital | Conditions: Multiple Myeloma of Bone | Status: RECRUITING